Gen1E-1124 is under clinical development by GEn1E Lifesciences and currently in Phase II for Acute Respiratory Distress Syndrome. According to GlobalData, Phase II drugs for Acute Respiratory Distress Syndrome have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gen1E-1124’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gen1E-1124 overview
Gen1E-1124 is under development for the treatment of acute lung injury (ALI), acute respiratory distress syndrome (ARDS), COVID-19 pneumonia. The drug candidates act by targeting mitogen activated protein kinase 14 (MAP Kinase p38 Alpha). It is administered through intravenous route.
See Also:
GEn1E Lifesciences overview
GEn1E Lifesciences is biotechnology company which is engaged in the research and development of immunomodulatory therapies for rare & inflammatory diseases. It is headquartered in Palo Alto, California, the US.
For a complete picture of Gen1E-1124’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.